摘要
Objective: This study was aimed to explore the expression of microRNA-32(miR-32) in multiple myeloma(MM), and study its association with β2-microglobulin and staging of MM by Durie-Salmon classification. Methods: The expression level of miR-32 in bone marrow mono-nuclear cells of MM were examined by real-time polymerase chain reaction(real-time PCR), and the correlations between the expression level of miR-32 and related clinic pathologic features β2-microglobulin, staging of MM by Durie-Salmon classification were further analyzed. Results: The expression of miR-32 in MM patients was obviously higher than that in normal control(P < 0.05). The expression of miR-32 in relapsed/ refractory MM patients was obviously higher than that in newly diagnosed MM patients. The expression of miR-32 in MM patients decreased after chemical therapy than that before treatment, especially in effective group(P < 0.05). There was no statistically significant change in ineffective/progress group after chemical therapy(P > 0.05).The expression of miR-32 was associated to staging of MM and β2-microglobulin level. Conclusion: Expression level of miR-32 in MM patients is significantly higher than that in normal bone marrow, these data indicated that miR-32 may play an important role in the development of MM. High-regulated expression of miR-32 was associated with β2-microglobulin and staging of MM by Durie-Salmon classification.
Objective： This study was aimed to explore the expression of microRNA-32（miR-32） in multiple myeloma（MM）, and study its association with β2-microglobulin and staging of MM by Durie-Salmon classification. Methods： The expression level of miR-32 in bone marrow mono-nuclear cells of MM were examined by real-time polymerase chain reaction（real-time PCR）, and the correlations between the expression level of miR-32 and related clinic pathologic features β2-microglobulin, staging of MM by Durie-Salmon classification were further analyzed. Results： The expression of miR-32 in MM patients was obviously higher than that in normal control（P 0.05）. The expression of miR-32 in relapsed/ refractory MM patients was obviously higher than that in newly diagnosed MM patients. The expression of miR-32 in MM patients decreased after chemical therapy than that before treatment, especially in effective group（P 0.05）. There was no statistically significant change in ineffective/progress group after chemical therapy（P 0.05）.The expression of miR-32 was associated to staging of MM and β2-microglobulin level. Conclusion： Expression level of miR-32 in MM patients is significantly higher than that in normal bone marrow, these data indicated that miR-32 may play an important role in the development of MM. High-regulated expression of miR-32 was associated with β2-microglobulin and staging of MM by Durie-Salmon classification.
基金
Supported by grants from the Qingdao Public Sphere Support Program of Qingdao Municipal Science and Technology Commission(No.2010KZJ-9)
Qingdao Public Health Bureau(No.2012-WSZD042)
